Themis is a Vienna-based vaccine developer. Together with the Institut Pasteur, it is now planning to use a measles vaccine construct to develop and start Zika vaccine trials within the next 12 months.
Themis has successfully extended its existing license agreement with Institut Pasteur in Paris, which grants the company a broad access to a well-established virus vaccine vector technology.
The safety and tolerability profile of Themis’ vector was already proven in a Phase I trial when the two partners used the technology platform for the development of a first-in-class Chikungunya vaccine, which will enter into Phase II later this year.
Now the platform will also be applied for the development of a Zika vaccine, a high priority project within Themis’ pipeline.
The technology uses a measles virus vaccine backbone, built from Tehmis’ Themaxyn platform. Since measles vaccines have already been successfully used in well over a billion individuals over the last 30–40 years, this suggests an excellent safety and immunogenicity profile,